|
2
|
Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, Palmer JM, Whiteman DC, Scolyer RA, Mann GJ, Thompson JF, Long GV, Barbour AP, Soyer HP, Garbe C, Herington A, Pollock PM, Hayward NK. The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. EBioMedicine 2015; 2:671-80. [PMID: 26288839 PMCID: PMC4534690 DOI: 10.1016/j.ebiom.2015.05.011] [Citation(s) in RCA: 73] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2015] [Revised: 05/09/2015] [Accepted: 05/09/2015] [Indexed: 01/08/2023] Open
Abstract
The overall 5-year survival for melanoma is 91%. However, if distant metastasis occurs (stage IV), cure rates are < 15%. Hence, melanoma detection in earlier stages (stages I–III) maximises the chances of patient survival. We measured the expression of a panel of 17 microRNAs (miRNAs) (MELmiR-17) in melanoma tissues (stage III; n = 76 and IV; n = 10) and serum samples (collected from controls with no melanoma, n = 130; and patients with melanoma (stages I/II, n = 86; III, n = 50; and IV, n = 119)) obtained from biobanks in Australia and Germany. In melanoma tissues, members of the ‘MELmiR-17’ panel were found to be predictors of stage, recurrence, and survival. Additionally, in a minimally-invasive blood test, a seven-miRNA panel (MELmiR-7) detected the presence of melanoma (relative to controls) with high sensitivity (93%) and specificity (≥ 82%) when ≥ 4 miRNAs were expressed. Moreover, the ‘MELmiR-7’ panel characterised overall survival of melanoma patients better than both serum LDH and S100B (delta log likelihood = 11, p < 0.001). This panel was found to be superior to currently used serological markers for melanoma progression, recurrence, and survival; and would be ideally suited to monitor tumour progression in patients diagnosed with early metastatic disease (stages IIIa–c/IV M1a–b) to detect relapse following surgical or adjuvant treatment. A seven-miRNA panel (MELmiR-7) detected the presence of melanoma with high sensitivity (93%) and specificity (≥ 82%). In serially collected stage IV specimens, members of the ‘MELmiR-7’ panel confirmed tumour progression in 100% of cases. The ‘MELmiR-7’ panel is superior to currently used serological markers for melanoma progression, recurrence, and survival.
Collapse
Key Words
- AGO2, argonaute RISC catalytic component 2
- AJCC, American Joint Committee on Cancer
- AUC, area under the curve
- AUROC, area under the receiver operator curve
- Biomarker
- CI, confidence interval
- Ct, threshold cycle
- DOR, diagnostic odds ratio
- Diagnostic
- FFPE, formalin-fixed paraffin-embedded
- HR, hazard ratio
- LDH, lactate dehydrogenase
- M1a, metastasis to skin, subcutaneous (below the skin) tissue, or lymph nodes in distant parts of the body, with a normal blood LDH level
- M1b, metastasis to the lungs, with a normal blood LDH level
- M1c, metastasis to any other organs, OR distant spread to any site along with an elevated blood LDH level
- MIA, Melanoma Institute of Australia
- Melanoma
- MiRNA
- MicroRNA
- N stage, nodal or number of lymph nodes stage
- NA, not applicable
- NM, nodular melanoma
- OR, odds ratio
- PD1, programmed cell death protein
- Prognostic
- RNA, ribonucleic acid
- S100B, S100 calcium-binding protein B
- SMM, superficial spreading melanoma
- USA, United States of America
- miR, microRNA
- miRNA, microRNA
Collapse
Affiliation(s)
- Mitchell S Stark
- Oncogenomics Group, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia ; School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia
| | - Kerenaftali Klein
- Statistics Unit, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia ; Clinical Trials and Biostatistics Unit, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia
| | - Benjamin Weide
- Department of Dermatology, University Medical Center, Tubingen, Germany
| | - Lauren E Haydu
- Melanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia
| | - Annette Pflugfelder
- Department of Dermatology, University Medical Center, Tubingen, Germany ; Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia
| | - Yue Hang Tang
- Surgical Oncology Group, The University of Queensland, School of Medicine, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia
| | - Jane M Palmer
- Oncogenomics Group, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia
| | - David C Whiteman
- Cancer Control Group, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia
| | - Richard A Scolyer
- Melanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia
| | - Graham J Mann
- Melanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia
| | - John F Thompson
- Melanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia
| | - Georgina V Long
- Melanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia
| | - Andrew P Barbour
- Surgical Oncology Group, The University of Queensland, School of Medicine, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia
| | - H Peter Soyer
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia
| | - Claus Garbe
- Department of Dermatology, University Medical Center, Tubingen, Germany
| | - Adrian Herington
- School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia
| | - Pamela M Pollock
- School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia
| | - Nicholas K Hayward
- Oncogenomics Group, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia
| |
Collapse
|